TherapeuticsMD, Inc.
Income Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|
| Revenue | $16.8M | $19.4M | $20.1M | $15.0M | $8.8M | $3.8M | $2.1M |
| Cost of Revenue | $2.6M | $4.2M | $4.5M | $3.7M | $2.0M | $1.3M | $947.1K |
| Gross Profit | $14.1M | $15.2M | $15.6M | $11.4M | $6.8M | $2.5M | $1.1M |
| Gross Margin | 84.3% | 78.4% | 77.6% | 75.6% | 77.7% | 64.7% | 54.6% |
| Operating Expenses | |||||||
| Research & Development | $33.9M | $53.9M | $72.0M | $43.2M | $13.6M | $4.5M | $107.2K |
| SG&A Expense | $57.7M | $51.3M | $28.7M | $22.1M | $19.0M | $14.1M | $6.4M |
| Operating Income | $-77.6M | $-90.3M | $-85.2M | $-54.0M | $-25.8M | $-16.1M | $-5.4M |
| Operating Margin | -462.7% | -466.3% | -422.9% | -359.6% | -294.1% | -423.0% | -259.9% |
| Interest Expense | — | — | — | $1.2M | $1.9M | $1.9M | $64.4K |
| Pretax Income | $-76.9M | $-89.9M | $-85.1M | $-54.2M | $-28.4M | $-35.1M | $-12.9M |
| Income Tax Expense | — | — | — | — | — | — | — |
| Net Income | $-76.9M | $-89.9M | $-85.1M | $-54.2M | $-28.4M | $-35.1M | $-12.9M |
| Net Margin | -458.5% | -464.3% | -422.4% | -360.8% | -323.8% | -919.9% | -618.4% |
| EPS (Basic) | $-0.37 | $-0.46 | $-0.49 | $-0.36 | $-0.22 | $-0.38 | $-0.21 |
| EPS (Diluted) | $-0.37 | $-0.46 | $-0.49 | $-0.36 | $-0.22 | $-0.38 | $-0.21 |
| Shares Outstanding (Basic) | 216.4M | 196.7M | 177.9M | 156.1M | 145.0M | 99.8M | 83.0M |
| Shares Outstanding (Diluted) | 216.4M | 196.7M | 177.9M | 156.1M | 145.0M | 99.8M | 83.0M |
| Dividends Per Share | — | — | — | — | — | — | — |